Bionano Genomics, Inc. (BNGO) Revenue History
Annual and quarterly revenue from 2016 to present
BNGO Revenue Over Time (2016–2025)
BNGO Revenue Growth History
5 of 9 years with positive growth- FY2016 revenue growth
- N/A
- FY2017 revenue growth
- +39.9%
- FY2018 revenue growth
- +26.3%
- FY2019 revenue growth
- -15.6%
- FY2020 revenue growth
- -16.1%
- FY2021 revenue growth
- +111.5%
- FY2022 revenue growth
- +54.6%
- FY2023 revenue growth
- +29.9%
- FY2024 revenue growth
- -14.8%
- FY2025 revenue growth
- -7.4%
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $8.2M | +21.4% |
| Q1 2026 | $6.7M | +3.6% |
| Q4 2025 | $8.0M | -2.6% |
| Q3 2025 | $7.4M | +21.3% |
| Q2 2025 | $6.7M | -13.4% |
| Q1 2025 | $6.5M | -26.4% |
| Q4 2024 | $8.2M | -23.9% |
| Q3 2024 | $6.1M | -34.8% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2025)
BNGO's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
BNGO Revenue Analysis (2016–2025)
Current Revenue & Growth
As of November 8, 2026, Bionano Genomics, Inc. (BNGO) generated trailing twelve-month (TTM) revenue of $30.2 million, reflecting exceptional growth of +21.4% year-over-year. The most recent quarter (Q2 2026) recorded $8.2 million in revenue, up 22.2% sequentially.
Historical Growth Trajectory
BNGO's 5-year compound annual growth rate (CAGR) stands at +27.4%, indicating outstanding long-term growth trajectory. The 3-year CAGR of +0.8% is below the 5-year average, signalling a growth deceleration in recent years. Bionano Genomics, Inc.'s highest annual revenue of $36.1 million was recorded in 2023.
Revenue by Segment
BNGO's revenue is primarily driven by Product (48%), Consumable Revenue (25%), and Software Revenue (12%). The diversified mix across segments reduces dependence on any single product line, which can support more resilient revenue in downturns.
Peer Comparison
Compared to Healthcare sector peers — including PACB (+4.4% YoY), CDNA (+38.9% YoY), and NTRA (+37.4% YoY) — BNGO has outperformed the peer group in revenue growth. Compare BNGO vs PACB →
BNGO Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| BNGOCurrent | $30M | +21.4% | +27.4% | -116.9% | |
 PACB | $160M | +4.4% | +15.2% | -348.5% | |
 CDNA | $380M | +38.9% | +14.6% | -6.6% | |
 NTRA | $2.3B | +37.4% | +42.6% | -13.4% | |
 ILMN | $4.3B | +5.9% | +6.0% | 19.9% | |
 VCYT | $517M | +17.5% | +34.5% | 14.3% |
BNGO Historical Revenue Data (2016–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $28.5M | -7.4% | $6.3M | 22.0% | $-33,339,000 | -116.9% |
| 2024 | $30.8M | -14.8% | $380K | 1.2% | $-103,983,000 | -337.9% |
| 2023 | $36.1M | +29.9% | $9.6M | 26.5% | $-215,245,000 | -596.0% |
| 2022 | $27.8M | +54.6% | $5.9M | 21.4% | $-131,698,000 | -473.7% |
| 2021 | $18.0M | +111.5% | $3.9M | 21.5% | $-77,101,000 | -428.8% |
| 2020 | $8.5M | -16.1% | $2.8M | 32.6% | $-38,551,000 | -453.4% |
| 2019 | $10.1M | -15.6% | $3.4M | 33.2% | $-25,874,906 | -255.4% |
| 2018 | $12.0M | +26.3% | $3.3M | 27.4% | $-20,415,085 | -170.1% |
| 2017 | $9.5M | +39.9% | $3.5M | 36.6% | $-23,218,808 | -244.3% |
| 2016 | $6.8M | - | $3.2M | 47.3% | $-21,168,416 | -311.6% |
BNGO Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
BNGO — Frequently Asked Questions
Quick answers to the most common questions about buying BNGO stock.
Is BNGO's revenue growth accelerating or slowing?
BNGO revenue growth is accelerating. TTM revenue reached $30M, up +21.4% year-over-year — ahead of the 5-year CAGR of +27.4%. This indicates the business is expanding faster than its historical baseline.
What is BNGO's revenue history from 2016 to 2026?
Bionano Genomics, Inc. (BNGO) revenue history spans 2016 to 2026. TTM revenue as of 2026 is $30M, growing at +21.4% YoY. The 5-year CAGR is +27.4%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is BNGO's long-term revenue growth rate (CAGR)?
Bionano Genomics, Inc.'s 5-year revenue CAGR of +27.4% reflects the sustained nature of its business expansion. As of 2026, the current YoY growth rate of +21.4% is above this long-term average. CAGR is the most reliable measure of sustained revenue momentum for BNGO.
Why does BNGO's quarterly revenue fluctuate?
BNGO quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Bionano Genomics, Inc.'s revenue data from 2016 to 2026 shows full historical quarterly detail on this page.
How is BNGO's revenue distributed by segment?
BNGO reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does BNGO's revenue compare to industry peers?
Bionano Genomics, Inc. (BNGO) with TTM revenue of $30M and +21.4% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.